Scientists provide first evidence that the drug sildenafil may benefit patients with Leigh syndrome, and particularly those carrying mutations in the mitochondrial gene MT-ATP6.
Navigating the journey to gain a diagnosis of Primary Mitochondrial Myopathy can be unnecessarily long, intensely stressful, and fraught with obstacles.
The countdown is on to Rare Disease Day 2025 which takes place on 28 February.
IMP is proud to support MITGEST. This international consortium brings together world-class academic experts in mitochondrial research.
The SIMPATHIC project is preparing to launch a clinical trial using Sildenafil as a potential treatment for Leigh syndrome.
IMP are delighted to have been asked to join the UK MitoCohort Oversight Committee. The UK Mitocohort is a UK wide database that collects clinical information on patients living with mito, to help advance understanding of the disease.
The PolG Foundation is committed to accelerating research efforts to develop effective treatments and, ultimately, a cure for POLG mitochondrial disorders.
During this year’s World Mitochondrial Disease Week, IMP hosted a free webinar on 19 September for LHON Awareness Day. The theme for the webinar was LHON and Gene Therapy: Where are they now?
On 7 November, biopharmaceutical company Khondrion announced the publication of results from their integrated Phase 2b clinical development programme which uses the drug sonlicromanol to target the underlying pathways of primary mitochondrial disease.
We had an amazing World Mitochondrial Disease Week this year. This year’s Awareness Week theme was Illuminate Tomorrow: Revitalize your energy. From 16-22 September, our member organisations and community around the world hosted events and took to social media to raise awareness about mito.